Skip to main
LUNG
LUNG logo

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 10%
Hold 30%
Sell 10%
Strong Sell 0%

Bulls say

Pulmonx Corp reported total revenue of $83.8 million for the full year 2024, marking a 22% increase from the previous year, driven by a 23% rise in domestic sales and a 20% growth in international revenue. The company also achieved record Q4 revenue of $23.8 million, which is a 23% increase year-over-year, indicating robust market performance and demand for its innovative medical solutions. Furthermore, the expansion of reimbursement coverage and advancements in patient selection technologies are expected to enhance adoption rates of its products, supporting a positive outlook for sustained revenue growth and market penetration.

Bears say

Pulmonx Corp's gross profit for the latest quarter stood at $17.6 million, reflecting a slight decline in gross margin to 74%, which may indicate challenges in maintaining profitability. A concerning financial trend is observed as the company's cash reserves decreased to $101.5 million from $107.8 million within a three-month span, raising questions about liquidity and operational sustainability. The company operates in a niche market with significant capital volatility, and while it addresses a high unmet medical need, this may not sufficiently counterbalance the financial risks posed by its declining financial metrics and reliance on a limited product range.

Pulmonx (LUNG) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 10% recommend Buy, 30% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 10 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.